您当前的位置: 首页 > 资源详情

PR Newswire,8月30日,New Research from nference and Mayo Clinic Suggests Monoclonal Antibody Treatments Prevent Hospitalization for COVID-19 Patients

编译者:YUTING发布时间:Sep 4, 2021点击量:291 来源栏目:最新研究

CAMBRIDGE, Mass., Aug. 30, 2021 /PRNewswire/ -- nference, the AI-driven health technology company, today announced publication of two studies providing important evidence that treatment of high-risk, mild to moderate COVID-19 patients with monoclonal antibodies significantly reduces risk of hospitalization.

In the most recent study, published in EClinicalMedicine, authors from nference and Mayo Clinic examined 696 high-risk patients with mild to moderate COVID-19 treated at Mayo Clinic facilities with casirivimab-imdevimab, along with a control cohort of 696 patients without casirivimab-imdevimab treatment. Results indicated a significant reduction in all-cause hospitalization in patients who received treatment with casirivimab-imdevimab, compared to propensity-matched untreated control.

The second study, published in Journal of Clinical Investigation, applied the same methodology used in the casirivimab-imdevimab research to 2,335 patients treated at Mayo Clinic facilities with bamlanivimab, with similar results. In both studies, treatment led to statistically significant lower rates of hospitalization compared with usual care.

"While trials with small cohorts led to authorization of casirivimab-imdevimab treatment for COVID-19 with monoclonal antibodies, clinical data has been needed to prove its effectiveness," said AJ Venkatakrishnan, PhD, vice president of scientific research at nference and co-author of both studies. "These two papers are the latest evidence of how our platform and our scientists are able to provide the real-world evidence necessary to accelerate research and development of important drugs."

"Once again, this real-world study suggests that when patients who are at high risk due to a range of comorbidities contract a mild or moderate case of COVID-19, this combination of monoclonal injections gives them a chance of a nonhospitalized recovery. In other words, they recover safely at home," says Raymund Razonable, MD, a Mayo Clinic infectious diseases specialist and senior author of both studies.

In the process of conducting these studies, nference employed its leading-edge augmented intelligence software, which uses proprietary natural language learning processes to rapidly synthesize and process biomedical data, including lab tests, clinical notes and structured Electronic Health Records (EHRs), producing accurate results and insights faster than ever before possible.

EClinicalMedicine is a peer-reviewed clinical journal from The Lancet that publishes original research to help frontline health professionals navigate the complex and rapid health transitions facing societies worldwide.

Journal of Clinical Investigation is published by the ASCI, a nonprofit honor organization of physician-scientists established in 1908, and includes research in basic and clinical biomedical science that will advance the practice of medicine.

提供服务:导出本资源
  1. 1 Nature,11月10日,Initial whole-genome sequencing and analysis of the host genetic contribution to COVID-19 severity and susceptibility
  2. 2 11月10日_研究人员分析宿主基因对COVID-19严重程度和易感性的影响
  3. 3 11月11日_新冠药物Remestemcel-L二期临床的中期分析结果积极
  4. 4 11月11日_CDC呼吁制定通用口罩规定以减少新冠传播
  5. 5 SSRN,2月20日,Dynamics of the Latest 2019 Novel Coronavirus Disease Epidemic in China: A Descriptive Study
  6. 6 SSRN,2月20日,Mental Health Problems and Social Media Exposure During COVID-19 Outbreak
  7. 7 SSRN,2月20日,Evaluating Incidence and Impact Estimates of the Coronavirus Outbreak from Official and Non-Official Chinese Data Sources
  8. 8 SSRN,2月20日,Clinical Characteristics and Treatment of Patients Infected with COVID-19 in Shishou, China
  9. 9 Nature,11月10日,Mobility network models of COVID-19 explain inequities and inform reopening
  10. 10 1月27日_Nature报道中国新型冠状病毒最新研究进展:病毒传播速度有多快?
  1. 1 11月22日_感染无害冠状病毒可增强针对SARS-CoV-2的免疫力
  2. 2 Medicalxpress,11月22日,Population impact of SARS-CoV-2 variants with enhanced transmissibility and/or partial immune escape
  3. 3 11月22日_科学家开发出一种可同时测量针对SARS-CoV-2的 T细胞和抗体反应的方法
  4. 4 Medicalxpress,11月22日,Pfizer says COVID shot 100% effective in adolescents after 4 months
  5. 5 11月18日_传播性增强和/或部分免疫逃逸的SARS-CoV-2变体对人群的影响
  6. 6 11月22日_辉瑞的COVID-19疫苗在接种4个月后对青少年的有效率为100%
  7. 7 Medicalxpress,11月18日,Simple, synthetic structure that mimics surface of SARS-CoV-2 mounts robust immune response in mice
  8. 8 11月18日_模拟SARS-CoV-2表面的简单合成结构在小鼠体内引发强大的免疫反应
  9. 9 11月17日_Zosano宣布在其微针贴片系统上成功配制COVID-19候选疫苗
  10. 10 11月18日_新分析预测疫苗针对SARS-CoV-2的保护作用

版权所有@2017中国科学院文献情报中心

制作维护:中国科学院文献情报中心信息系统部地址:北京中关村北四环西路33号邮政编号:100190